Dacomitinib | List of Frontiers open access articles

Original Research

Published on 13 Jun 2022

Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China

in Pharmacology of Anti-Cancer Drugs

Hong-Shuai Li
Guang-Jian Yang
Yi Cai
Jun-Ling Li
Hai-Yan Xu
Tao Zhang
Li-Qiang Zhou
Yu-Ying Wang
Jin-Liang Wang
Xing-Sheng Hu

Frontiers in Pharmacology

doi 10.3389/fphar.2022.919652

6,395 views
13 citations

Original Research

Published on 14 Dec 2021

Modelled Economic Analysis for Dacomitinib–A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China

in Thoracic Oncology

Yong-feng Yu
Luan Luan
Fan-fan Zhu
Peng Dong
Li-Heng Ma
Lan-ting Li
Lan Gao
Shun Lu

Frontiers in Oncology

doi 10.3389/fonc.2021.564234

5,011 views
7 citations

Case Report

Published on 14 Sep 2022

Drug-induced liver injury associated with dacomitinib: A case report

in Thoracic Oncology

Xuanxuan Wang
Anqi Huang
Yun Lu
Suyu Gao
Wen Hu
Hong Cheng

Frontiers in Oncology

doi 10.3389/fonc.2022.979462

3,079 views
8 citations

Case Report

Published on 25 Feb 2025

Case Report: Grade 4 pneumonitis occurred after thoracic radiotherapy and dacomitinib in a patient with lung adenocarcinoma

in Radiation Oncology

Ailing Liu
Junxu Wen
Kaikai Zhao
Liyang Jiang
Xiangjiao Meng

Frontiers in Oncology

doi 10.3389/fonc.2025.1436134

2,273 views
2 citations

Case Report

Published on 15 Apr 2021

Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment

in Molecular and Cellular Oncology

Hong-Shuai Li
Guang-Jian Yang
Yan Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.649843

5,595 views
15 citations

Review

Published on 05 Apr 2017

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib

in Pathology

Jon Zugazagoitia
Asunción Díaz
Elisabeth Jimenez
Juan Antonio Nuñez
Lara Iglesias
Santiago Ponce-Aix
Luis Paz-Ares

Frontiers in Medicine

doi 10.3389/fmed.2017.00036

8,170 views
11 citations

Original Research

Published on 28 Jul 2020

Deducing the Conformational Properties of a Tyrosine Kinase Inhibitor in Solution by Optical Spectroscopy and Computational Chemistry

in Theoretical and Computational Chemistry

Md. Lutful Kabir
Frederick Backler
Andrew H. A. Clayton
Feng Wang

Frontiers in Chemistry

doi 10.3389/fchem.2020.00596

3,833 views
5 citations

Case Report

Published on 09 Aug 2022

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases

in Molecular and Cellular Oncology

Yibin Li
Weixi Guo
Bin Jiang
Chengkun Han
Feng Ye
Jingxun Wu

Frontiers in Oncology

doi 10.3389/fonc.2022.863771

3,064 views
5 citations

Case Report

Published on 08 Oct 2025

Sequential tyrosine kinase inhibitor therapy for EGFR L747P-mutated lung adenocarcinoma in a renal transplant recipient: a 24-month case report

in Precision Medicine

Wenxiu Xie
Feng Chen
Lei Zhang
Baoquan Lin
Jia Ye
Zongyang Yu
Lei Gu
Wei Liu

Frontiers in Medicine

doi 10.3389/fmed.2025.1651584

1,321 views

Case Report

Published on 14 Apr 2022

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review

in Cancer Molecular Targets and Therapeutics

Hui Zhang
Yong Wang
Huaguo Wu
Shizhen Zhou
Shuo Li
Xiangji Meng
Rongjie Tao
Jinming Yu

Frontiers in Oncology

doi 10.3389/fonc.2022.877279

6,833 views
13 citations

Original Research

Published on 17 Jul 2025

Vitamin D ameliorates prediabetic cardiac injure via modulation of the ErbB4/ferroptosis signaling axis

in Inflammation

Yufan Miao
Yujing Zhang
Luoya Zhang
Hao Chen
Lulu Tang
Wenjie Li
Chenxi Gu
Lili Lang
Xing Li
Hanlu Song

Frontiers in Immunology

doi 10.3389/fimmu.2025.1626295

3,295 views

Original Research

Published on 29 Aug 2025

Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study

in Respiratory Pharmacology

Xu Miao
Yuan Liu
Xiaoqin Li
Rong Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1652750

2,941 views
2 citations

Case Report

Published on 02 Dec 2021

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report

in Molecular and Cellular Oncology

Qian Shen
Jingjing Qu
Zhen Chen
Jianying Zhou

Frontiers in Oncology

doi 10.3389/fonc.2021.760097

5,213 views
13 citations

Original Research

Published on 12 Oct 2018

Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations

in Women's Cancer

Euphemia Y. Leung
Marjan E. Askarian-Amiri
Dean C. Singleton
Carole Ferraro-Peyret
Wayne R. Joseph
Graeme J. Finlay
Reuben J. Broom
Purvi M. Kakadia
Stefan K. Bohlander
Elaine Marshall

Frontiers in Oncology

doi 10.3389/fonc.2018.00425

8,783 views
17 citations

Original Research

Published on 16 Sep 2022

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors

in Pharmacology of Anti-Cancer Drugs

Haiyan Xu
Guangjian Yang
Runze Liu
Yaning Yang
Weihua Li
Junling Li
Xuezhi Hao
Puyuan Xing
Yan Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2022.976731

7,895 views
11 citations

Original Research

Published on 21 Aug 2025

Comprehensive analysis based on the ubiquitination- and deubiquitylation-related genes reveals the function of NEURL3 in esophageal squamous cell carcinoma

in Cancer Immunity and Immunotherapy

Yi-Wei Lin
Hui-Er Li
Chao-Qun Hong
Zi-Ang Chen
Shu-Ping Liu
Yi-Wei Xu
Fang-Cai Wu
Yu-Hui Peng

Frontiers in Immunology

doi 10.3389/fimmu.2025.1632090

2,414 views
1 citation

Articles

Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China

Modelled Economic Analysis for Dacomitinib–A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China

Drug-induced liver injury associated with dacomitinib: A case report

Case Report: Grade 4 pneumonitis occurred after thoracic radiotherapy and dacomitinib in a patient with lung adenocarcinoma

Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib

Deducing the Conformational Properties of a Tyrosine Kinase Inhibitor in Solution by Optical Spectroscopy and Computational Chemistry

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases

Sequential tyrosine kinase inhibitor therapy for EGFR L747P-mutated lung adenocarcinoma in a renal transplant recipient: a 24-month case report

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review

Vitamin D ameliorates prediabetic cardiac injure via modulation of the ErbB4/ferroptosis signaling axis

Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report

Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors

Comprehensive analysis based on the ubiquitination- and deubiquitylation-related genes reveals the function of NEURL3 in esophageal squamous cell carcinoma